Who are S-Ketamine 0.5's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, continuous infusion of intravenous ketamine, acamprosate (Campral).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-ketamine-0-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

S-Ketamine 0.5 — Competitive Intelligence Brief

S-Ketamine 0.5 (S-Ketamine 0.5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Anesthesia; Psychiatry.

marketed NMDA receptor antagonist NMDA receptor Anesthesia; Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

S-Ketamine 0.5 (S-Ketamine 0.5) — Turku University Hospital. S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the NMDA receptor, blocking glutamate signaling in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
S-Ketamine 0.5 TARGET	S-Ketamine 0.5	Turku University Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
continuous infusion of intravenous ketamine	continuous infusion of intravenous ketamine	Ciusss de L'Est de l'Île de Montréal	marketed	NMDA receptor antagonist	NMDA receptor
acamprosate (Campral)	acamprosate (Campral)	University of North Carolina, Chapel Hill	marketed	NMDA receptor modulator	NMDA receptor (glutamate); GABA system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

Turku University Hospital · 3 drugs in this class
H. Lundbeck A/S · 2 drugs in this class
Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
Shalvata Mental Health Center · 2 drugs in this class
New York State Psychiatric Institute · 2 drugs in this class
Auris Medical AG · 1 drug in this class
AstraZeneca · 1 drug in this class
Alameda Health System · 1 drug in this class
Centre Hospitalier Universitaire de Nice · 1 drug in this class
Asker & Baerum Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S-Ketamine 0.5 — Competitive Intelligence Brief. https://druglandscape.com/ci/s-ketamine-0-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab